• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在一名经激发试验证实有轻度速发型反应的患者中成功进行地拉罗司重新激发试验并通过应对反应进行治疗：病例报告

Successful Deferasirox Rechallenge and Treating Through Reaction in a Patient with Challenge-Proven Mild Immediate Reaction: A Case Report.

作者信息

Sompornrattanaphan Mongkhon, Krikeerati Thanachit, Wongsa Chamard, Thongngarm Torpong, Yampayon Kittika

机构信息

Division of Allergy and Clinical Immunology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.

出版信息

J Asthma Allergy. 2020 Oct 30;13:557-561. doi: 10.2147/JAA.S271742. eCollection 2020.

DOI:10.2147/JAA.S271742
PMID:33154654
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7608632/
Abstract

This is the first report of successful deferasirox administration, using graded challenge and treating through, in a patient with mild immediate hypersensitivity reaction. Beginning with drug graded challenges could indicate the eliciting dose and reaction severity which are important for the management plan in the next step. This approach could be a safe shortcut in a stable patient with a mild reaction and a long avoidance period.

摘要

这是首例关于成功使用逐步激发并持续治疗的方法给予地拉罗司，治疗轻度速发型超敏反应患者的报告。从药物逐步激发开始可以确定引发剂量和反应严重程度，这对下一步的管理计划很重要。对于反应轻微且回避期较长的稳定患者，这种方法可能是一条安全的捷径。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f6eb/7608632/103402d7fa23/JAA-13-557-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f6eb/7608632/20089e3dd60a/JAA-13-557-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f6eb/7608632/53140736988c/JAA-13-557-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f6eb/7608632/103402d7fa23/JAA-13-557-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f6eb/7608632/20089e3dd60a/JAA-13-557-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f6eb/7608632/53140736988c/JAA-13-557-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f6eb/7608632/103402d7fa23/JAA-13-557-g0003.jpg

相似文献

1
Successful Deferasirox Rechallenge and Treating Through Reaction in a Patient with Challenge-Proven Mild Immediate Reaction: A Case Report.在一名经激发试验证实有轻度速发型反应的患者中成功进行地拉罗司重新激发试验并通过应对反应进行治疗：病例报告
J Asthma Allergy. 2020 Oct 30;13:557-561. doi: 10.2147/JAA.S271742. eCollection 2020.
2
Successful case of deferasirox slow desensitization in adults.成人地拉罗司缓慢脱敏成功案例。
Allergol Select. 2024 Aug 19;8:278-282. doi: 10.5414/ALX02501E. eCollection 2024.
3
Hypersensitivity reaction with deferasirox.地拉罗司引起的超敏反应。
J Pharmacol Pharmacother. 2015 Apr-Jun;6(2):105-6. doi: 10.4103/0976-500X.155491.
4
Deferasirox--an oral agent for chronic iron overload.地拉罗司——一种用于慢性铁过载的口服药物。
Ann Pharmacother. 2006 Jun;40(6):1110-7. doi: 10.1345/aph.1G566. Epub 2006 May 30.
5
Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions.评估一种去铁胺新片剂配方在长期输血后减轻慢性铁过载的效果。
Ther Clin Risk Manag. 2016 Feb 15;12:201-8. doi: 10.2147/TCRM.S82449. eCollection 2016.
6
Deferasirox for managing iron overload in people with thalassaemia.地拉罗司用于治疗地中海贫血患者的铁过载。
Cochrane Database Syst Rev. 2012 Feb 15(2):CD007476. doi: 10.1002/14651858.CD007476.pub2.
7
Effectiveness and Safety of Deferasirox in Thalassemia with Iron Overload: A Meta-Analysis.去铁酮治疗铁过载地中海贫血的有效性和安全性：一项荟萃分析。
Acta Haematol. 2019;141(1):32-42. doi: 10.1159/000494487. Epub 2018 Nov 30.
8
One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation.一项前瞻性随机试验的一年期结果，该试验比较了静脉放血术与地拉罗司治疗重型地中海贫血患儿根治性干细胞移植后铁过载的疗效。
Pediatr Blood Cancer. 2017 Jan;64(1):188-196. doi: 10.1002/pbc.26213. Epub 2016 Aug 31.
9
Hyperchloremic metabolic acidosis due to deferasirox in a patient with beta thalassemia major.继发于地拉罗司治疗的β-地中海贫血患者的高氯性代谢性酸中毒。
Ann Pharmacother. 2010 Jan;44(1):219-21. doi: 10.1345/aph.1M440. Epub 2009 Nov 24.
10
A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan.台湾地区输血依赖型地中海贫血患者铁过载应用地拉罗司的药物经济学评价。
J Formos Med Assoc. 2013 Apr;112(4):221-9. doi: 10.1016/j.jfma.2011.08.020. Epub 2012 Apr 30.

引用本文的文献

1
Successful case of deferasirox slow desensitization in adults.成人地拉罗司缓慢脱敏成功案例。
Allergol Select. 2024 Aug 19;8:278-282. doi: 10.5414/ALX02501E. eCollection 2024.
2
First Case Report of Deferiprone-Induced Anaphylactic Reaction.去铁酮诱发过敏反应的首例病例报告。
Cureus. 2024 Apr 8;16(4):e57847. doi: 10.7759/cureus.57847. eCollection 2024 Apr.

本文引用的文献

1
Breakthrough reactions during rapid drug desensitization: Clinical outcome and risk factors.快速药物脱敏过程中的突破性反应：临床结果和危险因素。
Ann Allergy Asthma Immunol. 2019 Jul;123(1):48-56.e1. doi: 10.1016/j.anai.2019.05.007. Epub 2019 May 18.
2
Successful desensitization to deferasirox in a paediatric patient with β-Thalassaemia major.一名重型β地中海贫血患儿成功实现对地拉罗司的脱敏治疗。
Pediatr Allergy Immunol. 2017 Mar;28(2):199-201. doi: 10.1111/pai.12677. Epub 2016 Dec 8.
3
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
去铁胺、去铁酮和地拉罗司铁螯合疗法治疗非输血依赖型地中海贫血综合征铁过载患者的疗效和安全性。
Drug Des Devel Ther. 2016 Jan 29;10:465-81. doi: 10.2147/DDDT.S79458. eCollection 2016.
4
Deferasirox desensitization.
J Allergy Clin Immunol Pract. 2016 Jan-Feb;4(1):171-2. doi: 10.1016/j.jaip.2015.09.007. Epub 2015 Oct 21.
5
Simultaneous Determination of Plasma Deferasirox and Deferasirox-Iron Complex Using an HPLC-UV System and Pharmacokinetics of Deferasirox in Patients With β-Thalassemia Major: Once-daily Versus Twice-daily Administration.使用高效液相色谱-紫外系统同时测定血浆地拉罗司和地拉罗司-铁复合物以及重型β地中海贫血患者地拉罗司的药代动力学：每日一次与每日两次给药
Clin Ther. 2015 Aug;37(8):1751-60. doi: 10.1016/j.clinthera.2015.05.506. Epub 2015 Jun 18.
6
Clinical pharmacology of deferasirox.地拉罗司的临床药理学
Clin Pharmacokinet. 2014 Aug;53(8):679-94. doi: 10.1007/s40262-014-0151-4.
7
Deferasirox: appraisal of safety and efficacy in long-term therapy.地拉罗司：长期治疗中的安全性与有效性评估
J Blood Med. 2013 Aug 5;4:101-10. doi: 10.2147/JBM.S35478. eCollection 2013.
8
Cross-talk between available guidelines for the management of patients with beta-thalassemia major.β-重型地中海贫血患者管理指南的交叉对话。
Acta Haematol. 2013;130(2):64-73. doi: 10.1159/000345734. Epub 2013 Mar 13.
9
Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia.口服地拉罗司每日 2 次给药可提高依赖输血的β-地中海贫血患者的疗效和耐受性。
Pediatr Blood Cancer. 2011 Mar;56(3):420-4. doi: 10.1002/pbc.22826.
10
Natural evolution of skin test sensitivity in patients allergic to beta-lactam antibiotics.
J Allergy Clin Immunol. 1999 May;103(5 Pt 1):918-24. doi: 10.1016/s0091-6749(99)70439-2.